Weaning Dexmedetomidine in Non-ICU Areas: An Implementation Effort.

Jean C Solodiuk, Erin Sweet, Christine Greco, Shannon F Manzi, Maeve Giangregorio, Adam Homoki, Liza Li, Laura Mansfield, Judy Mahoney, Monica E Kleinman
{"title":"Weaning Dexmedetomidine in Non-ICU Areas: An Implementation Effort.","authors":"Jean C Solodiuk,&nbsp;Erin Sweet,&nbsp;Christine Greco,&nbsp;Shannon F Manzi,&nbsp;Maeve Giangregorio,&nbsp;Adam Homoki,&nbsp;Liza Li,&nbsp;Laura Mansfield,&nbsp;Judy Mahoney,&nbsp;Monica E Kleinman","doi":"10.1097/PCC.0000000000002889","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To develop and implement clinical practice guidelines for safely weaning dexmedetomidine infusions in non-ICU areas.</p><p><strong>Design: </strong>Development, implementation, and analysis of effectiveness of clinical practice guidelines.</p><p><strong>Setting: </strong>Quaternary care academic free-standing pediatric hospital.</p><p><strong>Patients: </strong>Children, otherwise medically ready for transfer to non-ICU areas, who were undergoing a planned wean of a dexmedetomidine infusion.</p><p><strong>Interventions: </strong>Subject matter experts developed evidence-based guidelines for weaning dexmedetomidine in patients whose critical phase of illness had resolved.</p><p><strong>Measurements and main results: </strong>Searches identified no prospective studies of dexmedetomidine weaning. We identified two retrospective reviews of withdrawal symptoms and one on the use of clonidine. There were case studies on withdrawal symptoms. Guidelines were piloted on a cohort of 24 patients while in the ICU. The guidelines were then implemented in non-ICU areas for patients undergoing dexmedetomidine weaning after ICU transfer. Over a 2-year period (October 1, 2018, to September 30, 2020), 63 patients (1 mo to 18 yr old) successfully weaned dexmedetomidine in non-ICU areas. The median time to discontinuation of dexmedetomidine after transfer to non-ICU areas was 5.8 days (interquartile range, 4.75-15 d). Fifty-eight percent (n = 41) of all patients were considered high risk for dexmedetomidine withdrawal based on the dose, duration of exposure, and the risk of experiencing physiologic detriment with more than mild withdrawal. Twenty-nine patients (46%) exhibited no signs or symptoms of withdrawal while weaning per guidelines. For those with signs and symptoms of withdrawal, the most common were tachycardia (n = 26, 40%), agitation (n = 9, 14%), and hypertension (n = 9, 11%).</p><p><strong>Conclusions: </strong>Weaning dexmedetomidine in non-ICU areas is feasible and can be accomplished safely even among pediatric patients at high risk for withdrawal using standardized weaning guidelines. At our institution, implementation was associated with reduced ICU length of stay for patients recovering from critical illness.</p>","PeriodicalId":520744,"journal":{"name":"Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies","volume":" ","pages":"353-360"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PCC.0000000000002889","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Objectives: To develop and implement clinical practice guidelines for safely weaning dexmedetomidine infusions in non-ICU areas.

Design: Development, implementation, and analysis of effectiveness of clinical practice guidelines.

Setting: Quaternary care academic free-standing pediatric hospital.

Patients: Children, otherwise medically ready for transfer to non-ICU areas, who were undergoing a planned wean of a dexmedetomidine infusion.

Interventions: Subject matter experts developed evidence-based guidelines for weaning dexmedetomidine in patients whose critical phase of illness had resolved.

Measurements and main results: Searches identified no prospective studies of dexmedetomidine weaning. We identified two retrospective reviews of withdrawal symptoms and one on the use of clonidine. There were case studies on withdrawal symptoms. Guidelines were piloted on a cohort of 24 patients while in the ICU. The guidelines were then implemented in non-ICU areas for patients undergoing dexmedetomidine weaning after ICU transfer. Over a 2-year period (October 1, 2018, to September 30, 2020), 63 patients (1 mo to 18 yr old) successfully weaned dexmedetomidine in non-ICU areas. The median time to discontinuation of dexmedetomidine after transfer to non-ICU areas was 5.8 days (interquartile range, 4.75-15 d). Fifty-eight percent (n = 41) of all patients were considered high risk for dexmedetomidine withdrawal based on the dose, duration of exposure, and the risk of experiencing physiologic detriment with more than mild withdrawal. Twenty-nine patients (46%) exhibited no signs or symptoms of withdrawal while weaning per guidelines. For those with signs and symptoms of withdrawal, the most common were tachycardia (n = 26, 40%), agitation (n = 9, 14%), and hypertension (n = 9, 11%).

Conclusions: Weaning dexmedetomidine in non-ICU areas is feasible and can be accomplished safely even among pediatric patients at high risk for withdrawal using standardized weaning guidelines. At our institution, implementation was associated with reduced ICU length of stay for patients recovering from critical illness.

右美托咪定在非icu地区的断奶:一项实施努力。
目的:制定和实施非icu地区右美托咪定输注安全断奶的临床实践指南。设计:临床实践指南的制定、实施和有效性分析。单位:四级护理学术性独立儿科医院。患者:儿童,否则医学上准备转移到非icu区域,谁正在进行计划断奶右美托咪定输注。干预措施:主题专家制定了以证据为基础的指南,用于疾病关键期已经消退的患者断奶右美托咪定。测量和主要结果:搜索未发现右美托咪定断奶的前瞻性研究。我们确定了两项关于戒断症状的回顾性研究和一项关于使用可乐定的回顾性研究。有关于戒断症状的案例研究。指南在24名ICU患者队列中进行了试点。该指南随后在非ICU地区实施,用于ICU转移后右美托咪定断奶的患者。在2018年10月1日至2020年9月30日的2年时间里,63例患者(1个月至18岁)在非icu地区成功断奶右美托咪定。右美托咪定转至非icu区域后停药的中位时间为5.8天(四分位数范围4.75-15天)。58% (n = 41)的患者被认为是右美托咪定停药的高风险,基于剂量、暴露时间和轻度以上停药的生理损害风险。29名患者(46%)在断奶时没有表现出戒断症状或体征。对于那些有戒断症状和体征的患者,最常见的是心动过速(n = 26,40%)、躁动(n = 9,14%)和高血压(n = 9,11%)。结论:在非icu地区断奶右美托咪定是可行的,即使在使用标准化断奶指南的高危儿科患者中也可以安全完成。在我们的机构,实施与减少重症患者的ICU住院时间有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信